SI-BONE, Inc. (NASDAQ: SIBN) is a commercial-stage medical device company that develops and markets minimally invasive surgical implants for stabilization and fusion of the sacroiliac (SI) joint. The company’s flagship product, the iFuse Implant System, features a series of triangular titanium implants designed to replicate the anatomy of the SI joint and promote bone ongrowth. SI-BONE’s technology is intended to reduce pain and improve function in patients suffering from SI joint dysfunction due to degenerative sacroiliitis or traumatic disruption.
Founded in 2008 and headquartered in Santa Clara, California, SI-BONE received FDA clearance for the iFuse Implant System in 2009 and launched commercial operations in the United States the following year. Building on clinical evidence and surgeon feedback, the company introduced the iFuse-3D implant in 2019, incorporating a porous 3D-printed architecture to enhance osseointegration. SI-BONE supports its implants with a comprehensive training and education program for spine and pelvic surgeons, alongside a patient registry that tracks outcomes and safety data.
In addition to its U.S. footprint, SI-BONE markets the iFuse Implant System in Europe under CE marking, as well as in selected Asia-Pacific and Australian markets. The company collaborates with leading orthopedic and neurosurgical centers to advance research on SI joint disorders and to refine surgical techniques. Ongoing studies focus on long-term clinical benefits, expanded indications and health-economic outcomes associated with SI joint fusion.
SI-BONE is led by a management team with deep expertise in orthopedics, spine surgery, and medical device commercialization. The company’s executive leadership includes professionals with backgrounds at major device manufacturers and academic medical centers. Under this leadership, SI-BONE continues to invest in product innovation, clinical evidence generation and global market expansion to address the needs of patients with chronic lower back and pelvic pain.
